The Biomarkers Development and Discovery Congress focuses upon how the application of technology, experimental medicine and diagnostics can be implemented alongside the constraints of safety and containing toxicity, to achieve a successful business case scenario and the discovery of genuine biomarkers. Oxford international offers attendees a unique opportunity to network with senior-level R&D executives in the biomarkers sector from the major pharma and biotech companies.

Throughout the two day event, conference programme will address key issues including;

Current and future business models: Biomarkers as a means of empowering decision-making, reducing costs and increasing ROI
Imaging Technologies: Integration of biomarker Imaging techniques from pre-clinical to clinical
Regulation: Biomarkers as surrogate endpoints and ways of linking therapeutic approaches to diagnostics
Biomarkers for Molecular Diagnostics: Translation from Discovery to the Clinic
Efficacy models: Application of safety and efficacy biomarkers to personalised medicine and specific therapeutic areas
Toxicity biomarkers: safety, validation and efficacy testing

Application of Clinical Biomarkers: Validation of biomarkers to optimize early clinical development in and Incorporating Biomarker analyses into early clinical trials

The Biomarkers Discovery and Development Congress will take place on the 26th-27th February 2007 at The Midland Hotel, Manchester, UK.